Baylor University Medical Center at Dallas, part of Baylor Scott & White Health, is currently enrolling patients in ENDCOV-I: The Study of the Use of Nintedanib in Slowing Lung Disease in Patients with Fibrotic or Non-Fibrotic Interstitial Lung Disease (ILD) Related to COVID-19. Baylor Dallas is one of seven trial sites throughout the United States.
Like all transplant recipients, patients who have received a liver transplant have complex and unique medical needs. Physicians who are following these patients must be proactive about preventive care, recognize potential complications and manage any post-transplant conditions that develop.
Caring for family members with dementia and other forms of Alzheimer’s disease is a difficult task, and it is common for caregivers to feel overwhelmed due to the physical and emotional demands of the role. Researchers at Baylor Scott & White Research Institute’s (BSWRI) Center for Applied Health Research (CAHR) are engaged in groundbreaking studies to understand how to improve the quality of life for these caregivers. This work has taken on even greater implications now as COVID-19 creates greater isolation for caregivers making their role even more challenging.
Editorial by Todd Grazia, MD, Chief of Transplant Pulmonology, Baylor University Medical Center
When SARS Co-V2 arrived on U.S. shores in early 2020, physicians in all specialties faced an enormous learning curve. As many have said, we didn’t know what we didn’t know about the coronavirus. Some patients seemed to skate through the infection, while others were laid up with flu-like symptoms for a few weeks, and yet others developed severe respiratory failure from ARDS and died. Pulmonologists and intensivists were tasked with caring for and trying to treat a critical patient population whose lungs seemed to be systematically attacked, and often, permanently damaged by the virus. As the pandemic continued to rage and upend lives, transplant pulmonologists faced a daunting ethical dilemma: Should we or should we not consider lung transplantation for patients with irreversible lung damage from COVID-19?
